336 related articles for article (PubMed ID: 20723634)
1. Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention.
Mangiacapra F; Patti G; Peace A; Gatto L; Vizzi V; Ricottini E; D'Ambrosio A; Muller O; Barbato E; Di Sciascio G
Am J Cardiol; 2010 Sep; 106(5):619-23. PubMed ID: 20723634
[TBL] [Abstract][Full Text] [Related]
2. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study.
Patti G; Nusca A; Mangiacapra F; Gatto L; D'Ambrosio A; Di Sciascio G
J Am Coll Cardiol; 2008 Sep; 52(14):1128-33. PubMed ID: 18804738
[TBL] [Abstract][Full Text] [Related]
3. Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention.
Mangiacapra F; Barbato E; Patti G; Gatto L; Vizzi V; Ricottini E; D'Ambrosio A; Wijns W; Di Sciascio G
JACC Cardiovasc Interv; 2010 Mar; 3(3):318-23. PubMed ID: 20298992
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of high on-treatment platelet reactivity in Koreans receiving elective percutaneous coronary intervention (from results of the CROSS VERIFY study).
Park KW; Jeon KH; Kang SH; Oh IY; Cho HJ; Lee HY; Kang HJ; Park SK; Koo BK; Oh BH; Park YB; Kim HS
Am J Cardiol; 2011 Dec; 108(11):1556-63. PubMed ID: 21880289
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study).
Patti G; Pasceri V; Vizzi V; Ricottini E; Di Sciascio G
Am J Cardiol; 2011 Apr; 107(7):995-1000. PubMed ID: 21256470
[TBL] [Abstract][Full Text] [Related]
6. Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris.
Cuisset T; Hamilos M; Sarma J; Sarno G; Wyffels E; Vanderheyden M; Barbato E; Bartunek J; De Bruyne B; Wijns W
Am J Cardiol; 2008 Jun; 101(12):1700-3. PubMed ID: 18549843
[TBL] [Abstract][Full Text] [Related]
7. Correlation of platelet reactivity and C-reactive protein levels to occurrence of peri-procedural myocardial infarction in patients undergoing percutaneous coronary intervention (from the ARMYDA-CRP study).
Patti G; Mangiacapra F; Ricottini E; Cannatà A; Cavallari I; Vizzi V; D'Ambrosio A; Dicuonzo G; Di Sciascio G
Am J Cardiol; 2013 Jun; 111(12):1739-44. PubMed ID: 23538022
[TBL] [Abstract][Full Text] [Related]
8. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy.
Campo G; Fileti L; de Cesare N; Meliga E; Furgieri A; Russo F; Colangelo S; Brugaletta S; Ferrari R; Valgimigli M;
J Am Coll Cardiol; 2010 Oct; 56(18):1447-55. PubMed ID: 20951320
[TBL] [Abstract][Full Text] [Related]
9. High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention.
Mangiacapra F; De Bruyne B; Muller O; Trana C; Ntalianis A; Bartunek J; Heyndrickx G; Di Sciascio G; Wijns W; Barbato E
JACC Cardiovasc Interv; 2010 Jan; 3(1):35-40. PubMed ID: 20129566
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of in-laboratory high-dose clopidogrel loading versus routine pre-load in patients undergoing percutaneous coronary intervention: results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial.
Di Sciascio G; Patti G; Pasceri V; Gatto L; Colonna G; Montinaro A;
J Am Coll Cardiol; 2010 Aug; 56(7):550-7. PubMed ID: 20688209
[TBL] [Abstract][Full Text] [Related]
11. Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary intervention.
Muller O; Hamilos M; Bartunek J; Ulrichts H; Mangiacapra F; Holz JB; Ntalianis A; Trana C; Dierickx K; Vercruysse K; De Bruyne B; Wijns W; Barbato E
Am J Cardiol; 2010 Feb; 105(3):333-8. PubMed ID: 20102944
[TBL] [Abstract][Full Text] [Related]
12. Influence of platelet reactivity and response to clopidogrel on myocardial damage following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome.
Perez de Prado A; Cuellas C; Diego A; de Miguel A; Samaniego B; Alonso-Orcajo N; Carbonell R; Pascual C; Fernandez-Vazquez F; Calabozo RG
Thromb Res; 2009 Dec; 124(6):678-82. PubMed ID: 19411094
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of high-dose clopidogrel treatment (600 mg) less than two hours before percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes.
Feldman DN; Fakorede F; Minutello RM; Bergman G; Moussa I; Wong SC
Am J Cardiol; 2010 Feb; 105(3):323-32. PubMed ID: 20102943
[TBL] [Abstract][Full Text] [Related]
14. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention.
Buch AN; Singh S; Roy P; Javaid A; Smith KA; George CE; Pichard AD; Satler LF; Kent KM; Suddath WO; Waksman R
Am J Cardiol; 2007 Jun; 99(11):1518-22. PubMed ID: 17531573
[TBL] [Abstract][Full Text] [Related]
15. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes.
Cuisset T; Frere C; Quilici J; Morange PE; Nait-Saidi L; Mielot C; Bali L; Lambert M; Alessi MC; Bonnet JL
Thromb Haemost; 2007 Feb; 97(2):282-7. PubMed ID: 17264958
[TBL] [Abstract][Full Text] [Related]
16. Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre-treatment is associated with an increased ischemic risk during elective percutaneous coronary intervention.
Ang L; Thani KB; Ilapakurti M; Lee MS; Palakodeti V; Mahmud E
J Am Coll Cardiol; 2013 Jan; 61(1):23-34. PubMed ID: 23287370
[TBL] [Abstract][Full Text] [Related]
17. Effects of platelet and inflammatory system activation on outcomes in diabetic patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
Kuliczkowski W; Greif M; Gąsior M; Kaczmarski J; Pres D; Poloński L
Kardiol Pol; 2011; 69(6):531-7. PubMed ID: 21678284
[TBL] [Abstract][Full Text] [Related]
18. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy.
Pride YB; Wiviott SD; Buros JL; Zorkun C; Tariq MU; Antman EM; Braunwald E; Gibson CM;
Am Heart J; 2009 Sep; 158(3):e21-6. PubMed ID: 19699846
[TBL] [Abstract][Full Text] [Related]
19. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
Motovska Z; Kala P
Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
[TBL] [Abstract][Full Text] [Related]
20. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment.
Chen WH; Lee PY; Ng W; Tse HF; Lau CP
J Am Coll Cardiol; 2004 Mar; 43(6):1122-6. PubMed ID: 15028378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
